Clifford Chance has advised Marinomed Biotech AG on the company’s successful IPO. The company was listed on the official market (prime market segment) of the Vienna Stock Exchange on February 1, 2019, with shares traded under the symbol “MARI”.
Marinomed is a biopharmaceutical company, specializing in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases and has received multiple prestigious research awards for its activities.
The IPO issue comprised 299,000 new bearer shares. These consist of 260,000 shares from the base offer and 39,000 shares due to over-allotments. The issue price amounted to EUR 75.00 per share. The gross proceeds, assuming the entire greenshoe option is exercised, amount to EUR 22.4 million.
Based on the total number of 1,299,000 and the offer price of EUR 75 per share, the market capitalization of Marinomed amounts to approximately EUR 97.4 million. The free float is around 31%.
The bank consortium consisted of global coordinator Erste Group Bank AG and co-lead manager goetzpartners securities Limited.
The Clifford Chance team comprised partner George Hacket (Picture), senior associate David Santoro, associate Andrei Manea and transaction lawyer Anjana Parvathy (all Banking & Capital Markets, Frankfurt), partner Avrohom Gelber and associate Eric Naftel (both Tax, New York), as well as partners Glen Donath and George Kleinfeld together with counsel Jacqueline Landells (all Regulatory, Washington).
Involved fees earner: Glen Donath – Clifford Chance; Avrohom Gelber – Clifford Chance; George Hacket – Clifford Chance; George Kleinfeld – Clifford Chance; Jacqueline Landells – Clifford Chance; Andrei Manea – Clifford Chance; Eric Naftel – Clifford Chance; Anjana Parvathy – Clifford Chance; David Santoro – Clifford Chance;
Law Firms: Clifford Chance;
Clients: Marinomed Biotech AG ;